Results 61 to 70 of about 101 (70)
Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity. [PDF]
J Biol ChemSun X +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Diabetes
Introduction and Objective: Efficacy and safety of once-weekly (OW) s.c. and once-daily oral zenagamtide (amycretin) vs placebo (pbo) in adults with T2D were assessed in a phase 2b, 36-week, randomized, double-blind (within arm) study; OW s.c. data are reported. Methods: The OW s.c.
PABLO F. MORA +7 more
openaire +1 more source
Introduction and Objective: Efficacy and safety of once-weekly (OW) s.c. and once-daily oral zenagamtide (amycretin) vs placebo (pbo) in adults with T2D were assessed in a phase 2b, 36-week, randomized, double-blind (within arm) study; OW s.c. data are reported. Methods: The OW s.c.
PABLO F. MORA +7 more
openaire +1 more source
Diabetes
Introduction and Objective: To investigate the safety, tolerability, pharmacokinetics, and effects on body weight of single- (SAD) and multiple-ascending doses (MAD) of SC amycretin in people with overweight or obesity. Methods: In this single-center, double-blind study (NCT06064006), adults with BMI 27.0-39.9 kg/m2 and HbA1c <6.5%
KIRSTEN DAHL +6 more
openaire +1 more source
Introduction and Objective: To investigate the safety, tolerability, pharmacokinetics, and effects on body weight of single- (SAD) and multiple-ascending doses (MAD) of SC amycretin in people with overweight or obesity. Methods: In this single-center, double-blind study (NCT06064006), adults with BMI 27.0-39.9 kg/m2 and HbA1c <6.5%
KIRSTEN DAHL +6 more
openaire +1 more source
The Lancet
Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous amycretin administered over a treatment period of up to 36 weeks in participants with overweight or obesity.In this randomised, placebo-controlled, phase 1b ...
Kirsten, Dahl +11 more
openaire +2 more sources
Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous amycretin administered over a treatment period of up to 36 weeks in participants with overweight or obesity.In this randomised, placebo-controlled, phase 1b ...
Kirsten, Dahl +11 more
openaire +2 more sources
The Lancet
GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist.
Agnes, Gasiorek +9 more
openaire +2 more sources
GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist.
Agnes, Gasiorek +9 more
openaire +2 more sources
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
The LancetBernard, Khoo, Tricia M-M, Tan
openaire +2 more sources
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
MetabolismLinghua Fu +4 more
openaire +1 more source
Ergebnisse zur Sicherheit und Tolerabilität von Amycretin vorgelegt
Diabetologie und Stoffwechselopenaire +1 more source
Gewichtsreduktion durch Amycretin über 36 Wochen sicher und verträglich?
Diabetologie und Stoffwechselopenaire +1 more source